Application of next-generation imaging in biochemically recurrent prostate cancer.

Biochemical recurrence (BCR) following primary interventional treatment occurs in approximately one-third of patients with prostate cancer (PCa). Next-generation imaging (NGI) can identify local and metastatic recurrence with greater sensitivity than conventional imaging, potentially allowing for more effective interventions. This narrative review examines the current clinical evidence on the utility of NGI for patients with BCR.

A search of PubMed was conducted to identify relevant publications on NGI applied to BCR. Given other relevant recent reviews on the topic, this review focused on papers published between January 2018 to May 2023.

NGI technologies, including positron emission tomography (PET) radiotracers and multiparametric magnetic resonance imaging, have demonstrated increased sensitivity and selectivity for diagnosing BCR at prostate-specific antigen (PSA) concentrations <2.0 ng/ml. Detection rates range between 46% and 50%, with decreasing PSA levels for choline (1-3 ng/ml), fluciclovine (0.5-1 ng/ml), and prostate-specific membrane antigen (0.2-0.49 ng/ml) PET radiotracers. Expert working groups and European and US medical societies recommend NGI for patients with BCR.

Available data support the improved detection performance and selectivity of NGI modalities versus conventional imaging techniques; however, limited clinical evidence exists demonstrating the application of NGI to treatment decision-making and its impact on patient outcomes. The emergence of NGI and displacement of conventional imaging may require a reexamination of the current definitions of BCR, altering our understanding of early recurrence. Redefining the BCR disease state by formalizing the role of NGI in patient management decisions will facilitate greater alignment across research efforts and better reflect the published literature.

Prostate cancer and prostatic diseases. 2023 Sep 07 [Epub ahead of print]

Judd W Moul, Neal D Shore, Kenneth J Pienta, Johannes Czernin, Martin T King, Stephen J Freedland

Duke Cancer Institute and Division of Urology, Duke University, Durham, NC, USA., Carolina Urologic Research Center, Myrtle Beach, SC, USA., Johns Hopkins School of Medicine, Baltimore, MD, USA., David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, USA., Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA. .